ARB Candesartan Shows Neuroprotection in Parkinson’s Disease
In a groundbreaking study set to transform the landscape of Parkinson’s disease therapy, researchers have unveiled compelling evidence that the angiotensin receptor blocker (ARB) candesartan...
















